ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 2015, the company focuses on developing innovative therapies for cancer treatment, particularly through its expertise in immune-oncology. ALX Oncology is renowned for its lead product candidate, ALX148, which is designed to enhance the immune response against tumours by targeting the CD47 pathway, a unique approach that sets it apart in the competitive landscape. With a strong operational presence in key regions, ALX Oncology has made significant strides in clinical development, achieving notable milestones that underscore its commitment to advancing cancer care. The company’s dedication to pioneering solutions positions it as a leader in the fight against cancer, making substantial contributions to the evolving landscape of oncology therapeutics.
DitchCarbon Score
How does ALX Oncology Holdings Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ALX Oncology Holdings Inc.'s score of 18 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ALX Oncology Holdings Inc.'s reported carbon emissions
ALX Oncology Holdings Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the company may be engaged in broader industry initiatives aimed at sustainability and reducing environmental impact. As the landscape of corporate climate responsibility evolves, it is essential for companies like ALX Oncology to establish clear emissions reduction strategies and commitments to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ALX Oncology Holdings Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
